|
Mel Bridges, BAppSc, FAICD
Non-Executive Chairman
Mel Bridges joined the Alchemia Board as Non-Executive Chairman in September 2003. He has over 30 years experience in the biotechnology and healthcare industries. During this period, Mel founded and managed successful diagnostics, biotechnology and medical device businesses. He co-founded ASX listed companies Panbio Limited and ImpediMed Limited. During the past three years Mel has also served as a director of the following other listed companies: Appointed as director of ImpediMed Limited (September 1999) and subsequently as Chairman (March 2004), Chairman of Incitive Limited (appointed director in November 2007), Non-Executive Director of Benitec Limited (appointed October 2007).
Mel is also a Director of a number of private companies involved in the biotech industry.
Mel is a member of Alchemia's Audit and Risk Committee and a Fellow of the Australian Institute of Company Directors.
|
|
 | |
| |
| |
|
Peter Smith PhD
Chief Executive Officer and Managing Director
Peter Smith joined Alchemia in May 2006 and was appointed Head of Alchemia's Commercialization and Business Development Division. He was appointed to the role of CEO and Managing Director on 26 April 2007. Prior to joining the company Peter was acting Chairman and CEO of Cerylid Biosciences Limited from 2005 to 2006 and CEO and Managing Director of Amrad (appointed 16 October 2003; resigned 19 May 2005). Previously Peter founded UK biotech company Onyvax and was a top-rated pharmaceutical industry analyst at European Investment Banks UBS and HSBC. Peter holds a PhD in Biochemistry and a BA from Cambridge University. |
|
 | |
| |
| |
|
| |
| |
|
|
| |
|
|
Tracie Ramsdale, PhD
Non-Executive Director
Tracie Ramsdale is one of the founders of Alchemia and has led the company's development as its General Manager and Chief Executive Officer from 1998 to 2007. Tracie joined the Alchemia Board in July 2003. Tracie originally trained as a synthetic organic chemist, obtaining a Master of Pharmacy from the Victorian College of Pharmacy in 1987 and a PhD in Biochemistry from the University of Queensland in 1994.
Before establishing Alchemia, Tracie was a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland (Institute for Molecular Bioscience) from 1994 to 1998. Prior to this Tracie held research appointments at the Victorian College of Pharmacy and Bond University. Tracie is a Non-Executive Director of Incitive Limited (appointed November 2007). She is a member of the Australian Institute of Company Directors.
|
|
 | |
| |
| |
|
Nerolie Withnall, BA LLB MAICD
Non-Executive Director
Nerolie Withnall joined the Board in October 2003. She is a former partner of Minter Ellison Lawyers. In 2001 she retired from the law after practising for more than 30 years in Sydney, Darwin and Brisbane.
She is a Director of Campbell Brothers Ltd (appointed 13 December1994), Pan Australian Resources Limited (appointed 21 May 1996), Hedley Gaming & Leisure Property Partners Limited (appointed 25 June 2006), Computershare Limited (appointed July 2008) (all ASX listed companies), and of Queensland's Major Sports Facilities Authority. Nerolie is also Chairman of The Brisbane Institute and a Director of the National Seniors Foundation and a number of privately owned companies. She is Deputy President of the Takeovers Panel, a member of the Corporations and Markets Advisory Committee and a member of the Senate of the University of Queensland.
Nerolie is a member and Chairman of Alchemia's Audit and Risk Committee. |
|
 | |
| |
| |
|
Carlo Montagner
Non-Executive Director
Carlo Montagner joined the Board in March 2008. Mr. Montagner has held numerous executive positions abroad with high profile pharmaceutical companies, including President of Abraxis Bioscience; Executive Vice President and Head of Global Oncology for Schering, A.G.; Head of Oncology and Cardiovascular for Sanofi-Aventis Japan and Global Senior Director of Marketing and Medical Affairs, managing the commercialization of Taxotere. Mr. Montagner returned to Australia in 2008 and is currently President PanAsia for Abraxis Bioscience, and CEO of privately held Specialised Therapeutics Australia. He also holds a non-executive director position with Circadian Technologies Ltd. Mr Montagner has been a member of the Australian Institute of Company Directors since 1998.
Carlo is a member of Alchemia's Audit and Risk Committee and the Company's Remuneration Committee. |
|
 | |
| |
| |
 | |
|